文献速递慢性肾脏病肾血管病与高血压血液净化与透析

新发房颤与eGFR降低患者的心力衰竭、心梗、终末期肾病及死亡风险

Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR.
PubMed 文献 · Am J Kidney Dis · 2017-11-16

基于加拿大安大略省142万eGFR<90mL/min/1.73m²成人的回顾性队列发现,新发房颤与心衰、心梗、终末期肾病和全因死亡风险升高相关,且风险在房颤诊断后6个月内尤为突出。

要点

  • eGFR<90患者新发房颤后6个月内不良事件风险极高。
  • 房颤与心衰、心梗、终末期肾病和死亡风险独立相关。
  • eGFR水平修饰房颤对心衰风险的影响(交互P<0.05)。

核心结论

  • 在eGFR<90mL/min/1.73m²患者中,新发房颤与心衰、心梗、终末期肾病和全因死亡风险升高相关,且6个月内风险最高。

研究设计与样本

  • 加拿大安大略省基于人群的回顾性队列研究,纳入2006年4月1日至2015年3月31日期间1,422,978例eGFR<90mL/min/1.73m²的成人居民。

主要发现

  • 倾向评分匹配后(93,414对),房颤组6个月内CHF发生率3.04% vs 0.28%(sHR 11.57,95%CI 10.26-13.05)。
  • 6个月内MI发生率0.97% vs 0.21%(sHR 4.76,95%CI 4.17-5.43),ESKD发生率0.16% vs 0.03%(sHR 5.84,95%CI 3.82-8.93)。
  • 6个月内全因死亡率6.11% vs 2.50%(HR 2.62,95%CI 2.50-2.76)。
  • 6个月后CHF发生率6.87% vs 2.87%(sHR 2.64,95%CI 2.55-2.74),MI 2.21% vs 1.81%(sHR 1.24,95%CI 1.18-1.30)。
  • 6个月后ESKD 0.52% vs 0.32%(sHR 1.75,95%CI 1.57-1.95),全因死亡15.55% vs 15.10%(HR 1.07,95%CI 1.04-1.10)。

关键数值与推荐

  • eGFR水平修饰房颤对CHF的影响(交互P<0.05)。
  • 分析考虑了死亡竞争风险。

临床怎么用

  • 对eGFR<90且新发房颤患者,尤其6个月内,应加强心衰、心梗、ESKD及死亡风险监测与干预。

局限性

  • 观察性设计不能确定因果关系。
  • 仅使用单次门诊eGFR测量。
  • 未纳入用药数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association of atrial fibrillation (AF), estimated glomerular filtration rate (eGFR), and adverse events remains unknown. STUDY DESIGN: Population-based retrospective cohort study from Ontario, Canada. SETTING & PARTICIPANTS: 1,422,978 adult residents with eGFRs < 90mL/min/1.73m2 from April 1, 2006, through March 31, 2015. FACTOR: A diagnosis of AF at hospitalization. OUTCOMES: Congestive heart failure (CHF), myocardial infarction (MI), end-stage kidney disease, all-cause mortality. RESULTS: All adverse events were more frequent in individuals with AF (93,414 propensity score matched) compared to no AF, and this difference was more pronounced within the first 6 months of the index date (CHF: 3.04% [AF] vs 0.28% [no AF], subdistribution HR [sHR] of 11.57 [95% CI, 10.26-13.05]; MI: 0.97% [AF] vs 0.21% [no AF], sHR of 4.76 [95% CI, 4.17-5.43]; end-stage kidney disease: 0.16% [AF] vs 0.03% [no AF], sHR of 5.84 [95% CI, 3.82-8.93]; and all-cause mortality: 6.11% [AF] vs 2.50% [no AF], HR of 2.62 [95% CI, 2.50-2.76]) than in the period more than 6 months after the index date (CHF: 6.87% [AF] vs 2.87% [no AF], sHR of 2.64 [95% CI, 2.55-2.74]; MI: 2.21% [AF] vs 1.81% [no AF], sHR of 1.24 [95% CI, 1.18-1.30]; end-stage kidney disease: 0.52% [AF] vs 0.32% [no AF], sHR of 1.75 [95% CI, 1.57-1.95]; and all-cause mortality: 15.55% [AF] vs 15.10% [no AF], HR of 1.07 [95% CI, 1.04-1.10]). The results accounted for the competing risk for mortality. eGFR level modified the effect of AF on CHF (P for interaction < 0.05). LIMITATIONS: Observational study design does not permit determination of causality; only a single outpatient eGFR measure was used; medication data were not included. CONCLUSIONS: Incident AF is associated with a high risk for adverse outcomes in patients with eGFRs < 90mL/min/1.73m2. Because the risk is exceedingly high within the first 6 months after AF diagnosis, therapeutic interventions and monitoring may improve outcomes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, et al. Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR. Am J Kidney Dis. 2017. PMID: 29153994. doi:10.1053/j.ajkd.2017.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。